Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Retained Earnings (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Retained Earnings for 6 consecutive years, with -$504.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 990100.0% to -$504.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$504.9 million, a 990100.0% decrease, with the full-year FY2025 number at -$504.9 million, down 990100.0% from a year prior.
  • Retained Earnings was -$504.9 million for Q4 2025 at TScan Therapeutics, down from -$481.9 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $51000.0 in Q4 2024 to a low of -$504.9 million in Q4 2025.
  • A 5-year average of -$231.2 million and a median of -$205.0 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: surged 100.02% in 2024, then crashed 990100.0% in 2025.
  • TScan Therapeutics' Retained Earnings stood at -$92.2 million in 2021, then tumbled by 71.86% to -$158.4 million in 2022, then plummeted by 56.33% to -$247.6 million in 2023, then skyrocketed by 100.02% to $51000.0 in 2024, then plummeted by 990100.0% to -$504.9 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Retained Earnings are -$504.9 million (Q4 2025), -$481.9 million (Q3 2025), and -$446.2 million (Q2 2025).